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I read with interest the article by Tan et al. [1] de-
scribing a five-gene reverse transcription-PCR assay
for pre-operative classification of breast fibroepithelial
lesions (FELs).
I would like to raise three points, however: one regard-
ing the presentation of the statistics in this paper, and
two about the practical application of this assay.
Firstly, it is not clear whether the test group is repre-
sentative of the prevalence of phyllodes tumours (PT) in
their population. Because the rate of cases diagnosed as
fibroadenoma (FA) on core biopsy with a subsequent
diagnosis of PT on excision in their test group is more
than four times that which they reported previously as
part of a multi-centre study on a series of 4163 consecu-
tive such cases [2], it would appear more likely that the
test group is not representative. If this is the case, their
calculation of the positive predictive value (PPV) and the
negative predictive value (NPV) (which are dependent
on disease prevalence) is in error and leaves it unclear
how this assay would perform in practice.
Secondly, in relation to Tan et al.’s indeterminate FELs
on core biopsy, because 21 of the 22 of these in their test
group turned out to be PTs on excision, their histological
classification as indeterminate FELs on core biopsy
performed better than their five-gene assay at predict-
ing PTs on excision (94.5 % vs 82 %). Again, however,
this is likely to be a selected group, as the authors
quote a rate of 41–63 % for these cases in their previous
publication [2].
Finally, regarding the rare cases which on excision
turn out to be PT following a histological diagnosis of
FA on core biopsy—there were only 16 such cases in
their previous study of 4163 consecutive cases—the
practicality of applying this molecular assay in identifying
these cases is questionable. To identify one true positive,
260 cases would need to be tested, and it is likely that test-
ing would generate more false positive than true positive
results.
While it remains an interesting avenue of investigation
for these challenging lesions, the general applicability of
the findings in this study appears limited by its design
and by the practical difficulties inherent in identifying
very rare events. It may be that, as yet, what we know of
the molecular characteristics of this complex group of
tumours does not add enough to be of practical value in
their pre-operative classification.
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We appreciate the comments offered by Dr Joseph
Loane on our publication [1]. To address the issues
raised, it is important to describe the cohort involved in
our paper and that of the multi-centre study [2]. Our
assay was developed using an initial test set of 48 sam-
ples of FAs and PTs, including paired core biopsies with
subsequent excisions. This was then validated on 230
core biopsies, of which 131 were diagnosed as FAs with
event-free follow-up of at least 2 years, and on 99 FAs
and PTs (n = 58 and n = 41, respectively) concluded by
surgical excisions with corresponding pre-operative core
biopsies, including 22 cases in which the core biopsy
diagnosis was indeterminate. A large proportion of core
biopsies with subsequent excisions serving as the refer-
ence diagnosis was selected. In contrast, the multi-centre
study reviewed consecutive core biopsies diagnosed as un-
equivocal FAs which would not ordinarily be excised, de-
termining the likelihood of subsequent occurrence of PT
on follow-up as 0.38 %. This study concluded that a firm
diagnosis of unambiguous FA on core biopsy was reliable
and safe with adequate imaging and follow-up [2]. It is
therefore not unexpected that the rate of subsequent diag-
nosis of PT among core biopsies in our validation cohort
was substantially higher than in the multi-centre study, as
the aim and selection criteria were different. The PPV and
NPV calculated in our study were based on the validation
cohort used, and we agree that an optimal PPV and
NPV could be derived from application of the assay
in a prospective hospital-based cohort evaluating key
outcomes including recurrence. This would be best
addressed by a follow-up study. Notably, PTs are more
common in Asian women [3].
The indeterminate FELs diagnosed pre-operatively were
histologically inconclusive; it is unclear how indeterminate
calls could be compared or inferred as performing better
than the assay. Discordance (4/22; 18 %) between the
assay and reference diagnosis among FELs may reflect
tumour heterogeneity because the assay was performed
on limited core biopsy material, while the reference
diagnosis was based on surgical excisions.
Distinguishing cellular FELs on core biopsy into FA vs
PT remains challenging, with multiple studies attempting
to use a variety of microscopic parameters, none of which
are uniformly predictive [4, 5]. An adjunctive objective
practical assay such as ours to aid decision-making will be
helpful, especially if further validated in larger studies in a
multi-centre prospective setting.
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